Compare GEOS & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEOS | TNXP |
|---|---|---|
| Founded | 1980 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.6M | 194.9M |
| IPO Year | 1997 | N/A |
| Metric | GEOS | TNXP |
|---|---|---|
| Price | $23.17 | $15.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $70.00 |
| AVG Volume (30 Days) | 191.5K | ★ 474.2K |
| Earning Date | 02-04-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $110,803,000.00 | $10,299,000.00 |
| Revenue This Year | N/A | $2.96 |
| Revenue Next Year | N/A | $750.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.51 | $6.76 |
| 52 Week High | $29.89 | $69.97 |
| Indicator | GEOS | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 71.32 | 42.10 |
| Support Level | $18.15 | $14.97 |
| Resistance Level | $23.61 | $15.79 |
| Average True Range (ATR) | 1.56 | 0.80 |
| MACD | 0.81 | -0.04 |
| Stochastic Oscillator | 93.37 | 29.07 |
Geospace Technologies Corp is engaged in designing and manufacturing sophisticated technology solutions for applications in smart water management, energy exploration, as well as industrial and Internet of Things. Its seismic equipment is used to locate, characterize, and monitor hydrocarbon reservoirs and is also marketed for vibration monitoring, security, and geotechnical uses. The company also produces non-seismic products such as Hydroconn cables, imaging equipment, remote shutoff water valves, and IoT platforms, and provides contract manufacturing services. The company's business segments includes Smart Water, Energy Solutions and Intelligent Industrial. The majority of its revenue is generated from the Energy Solutions segment.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.